Welcome to our dedicated page for Aditxt news (Ticker: ADTX), a resource for investors and traders seeking the latest updates and insights on Aditxt stock.
Aditxt, Inc. (NASDAQ: ADTX) regularly issues news and regulatory updates that describe its activities as a social innovation platform accelerating promising health innovations. Company news often highlights developments across its programs in immune health, precision diagnostics, autoimmunity, cancer and early disease detection, infectious diseases, and women’s health, as well as platform-level initiatives such as the bitXbio™ strategy.
Recent announcements have focused on the evolution of Aditxt’s bitXbio™ framework, which the company describes as a transformational approach intended to connect public markets, blockchain and Web3 concepts, digital asset treasuries, and life sciences operating companies. News items have discussed proxy proposals related to an Employee Stock Purchase Plan, equity incentive plan changes, and a non-binding advisory vote on a proposed name change from “Aditxt, Inc.” to “bitXbio, Inc.”
Updates about Aditxt’s subsidiaries and ventures are another recurring theme. For example, the company has reported on Adimune, a wholly owned subsidiary developing a DNA-based therapeutic platform to reprogram the immune system, including information on its patent portfolio and plans related to first-in-human trials for conditions such as type 1 diabetes and stiff person syndrome. News has also covered Pearsanta, Aditxt’s precision diagnostics subsidiary, including the start of enrollment in a clinical study of the Mitomic® Endometriosis Test (MET™) and Pearsanta’s work with Mitomic® and Adductomics testing platforms.
Capital markets and corporate governance developments appear frequently in Aditxt’s news flow. The company has issued press releases about a 1-for-113 reverse stock split intended to address Nasdaq’s minimum bid price requirement, as well as proxy statements and special meetings to approve issuances of common stock underlying preferred stock and warrants, an Employee Stock Purchase Plan, and changes to its equity incentive plan.
Investors and observers who follow ADTX news can use this stream of press releases and related filings to track how Aditxt describes the progress of its platform strategy, its health-focused programs, its relationships with companies such as Evofem Biosciences, and its ongoing corporate and capital structure actions. Returning to this page provides a way to review the company’s official communications over time.
Aditxt (NASDAQ: ADTX) and Evofem Biosciences (OTCQB: EVFM) have signed a Second Amendment to their merger agreement, extending the timeline for Aditxt's $3 million funding to Evofem. The acquisition is now targeted to close in Q4 2024. Evofem aims to grow revenue through its three-pronged strategy: increasing U.S. sales of Phexxi® and SOLOSEC®, expanding its portfolio, and pursuing international partnerships. Aditxt plans to introduce four health-focused programs, including women's health through the Evofem merger. The deal's completion depends on shareholder approvals and Aditxt securing sufficient capital.
Aditxt (NASDAQ: ADTX) subsidiary Pearsanta has submitted a $2 million grant application to the DoD's Prostate Cancer Research Program. The funding aims to advance clinical trials for the Mitomic® Prostate Test (MPT™), a blood test for early detection of clinically significant prostate cancer. The proposed study involves validating MPT™ and conducting a randomized clinical trial with up to 1,000 men to evaluate its effectiveness in reducing unnecessary biopsies.
The prostate cancer diagnostic market is expected to grow from $6.2 billion in 2023 to $11.5 billion by 2032. Prostate cancer affects 1 in 8 men, with an estimated 299,010 new cases and 35,250 deaths expected in the US this year. Pearsanta's Mitomic Technology Platform uses mitochondrial DNA mutations for early disease detection, focusing on various cancers and conditions like endometriosis.
Aditxt Inc. (NASDAQ: ADTX) announced the appointment of Christopher Mitton as President of its subsidiary, Pearsanta Inc. Mitton brings over 20 years of leadership experience in medical diagnostics, focusing on personalized healthcare and molecular oncology. Pearsanta specializes in developing diagnostic tests for cancer, cardiology, immunology, gut health, and chronic conditions using proprietary platforms like Mitomic® Technology and AditxtScore™.
Under Mitton's leadership, Pearsanta aims to complete clinical validation studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™), with plans for commercial launch as laboratory developed tests. The company is also finalizing validation for the Mitomic® Ovarian Test (MOT™). Pearsanta's strategy includes leveraging existing partnerships and internal synergies within Aditxt to drive revenue and accelerate test adoption globally.
Aditxt Inc. (NASDAQ: ADTX) has announced a third amendment to its arrangement agreement with Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF). Key changes include:
1. Extending the Outside Date to November 19, 2024
2. Requiring Appili to convene a shareholder meeting promptly
3. Changing the deadline for Aditxt's financing completion to October 18, 2024
4. Making the Continuance a condition for completing the arrangement
The transaction remains subject to Aditxt raising at least $20 million in financing and other customary conditions. Upon completion of the Appili and Evofem Biosciences transactions, Aditxt plans to introduce two new programs focused on public health and women's health, expanding its current immune health and precision health programs.
Evofem Biosciences (OTCQB: EVFM) is addressing concerns about the impact of GLP-1 receptor agonists on oral contraceptive effectiveness. These medications, used for obesity and type 2 diabetes treatment, can cause gastrointestinal side effects that may reduce oral contraceptive absorption. Evofem offers Phexxi, a hormone-free, on-demand contraceptive gel, as a non-oral alternative.
Phexxi maintains the vagina's acidic pH, creating an environment inhospitable to sperm. It's particularly suitable for women using GLP-1 medications who are concerned about potential drug interactions affecting their birth control efficacy. Evofem's CEO, Saundra Pelletier, emphasizes the importance of understanding these interactions and providing alternative contraceptive options for women managing chronic conditions like obesity and diabetes.
Evofem Biosciences reported financial results for Q2 2024, showing significant improvements:
- Net product sales increased 69% to $4.2 million
- Operating loss improved 81% to $1.4 million
- Total operating expenses decreased 43% to $5.5 million
Key developments include:
- Acquisition of global rights to SOLOSEC, a single-dose antibiotic for sexual health infections
- Licensing of Phexxi commercial rights in the Middle East
- Partnership with Hello Alpha to offer Phexxi as hormone-free contraception
- 7.4% lower rebate on Phexxi prescriptions to Medi-Cal
- Issuance of fifth U.S. patent for Phexxi
The company received $2.0 million from Aditxt, Inc. to reinstate the Merger Agreement and through preferred stock sale.
Aditxt (NASDAQ: ADTX) announced the successful passage of all nine proposals at its recent annual shareholders' meeting, setting the stage for its 2024 and 2025 strategic plans. Key approvals include:
1. Election of directors
2. Ratification of auditors
3. Issuance of shares for Series B-1 and B-2 Convertible Preferred Stock
4. Equity Line of Credit (ELOC) proposal for up to $150 million
5. Increase in authorized shares from 100 million to 1 billion
6. Reverse stock split authority (1:5 to 1:200)
7. Amendment to the 2021 Omnibus Equity Incentive Plan
These approvals provide Aditxt with flexibility and potential resources to advance its strategic initiatives in immune health, precision health, public health, and women's health programs.
Aditxt, Inc. (NASDAQ: ADTX) has closed a $1.2 million registered direct offering priced at-the-market under Nasdaq rules. The offering involved the sale of 1,130,189 shares of common stock (or equivalents) at $1.06 per share. H.C. Wainwright & Co. acted as the exclusive placement agent. Aditxt plans to use $500,000 of the net proceeds to fund obligations under its Amended and Restated Merger Agreement with Evofem Biosciences, Inc., with the remainder allocated for working capital and general corporate purposes. The offering was made pursuant to a shelf registration statement on Form S-3 filed with the SEC.
Aditxt (NASDAQ: ADTX) has announced a $1.2 million registered direct offering priced at-the-market under Nasdaq rules. The company will sell 1,130,189 shares of common stock (or equivalents) at $1.06 per share to institutional investors. The offering is expected to close around August 9, 2024. H.C. Wainwright & Co. is the exclusive placement agent. Aditxt plans to use $500,000 of the net proceeds to fund obligations under its merger agreement with Evofem Biosciences, with the remainder for working capital and general corporate purposes. The offering is made pursuant to a shelf registration statement on Form S-3 filed with the SEC.
Aditxt (NASDAQ: ADTX) announced that its subsidiary, Pearsanta, has submitted a proposal for the Clinical Trial Translational Endpoints Research Award to validate a novel assay for early detection of ovarian cancer. The proposal aims to validate the Mitomic Ovarian Test (MOT), which uses mitochondrial DNA mutations as early indicators of ovarian cancer. The study will enroll 100 subjects with ovarian cancer and 200 negative controls, aiming to detect significant diagnostic accuracy (AUC > 0.85) at each stage of epithelial ovarian cancer vs. controls.
The ovarian cancer diagnostic market is projected to grow from $1.5 billion in 2023 to $2.7 billion by 2032. Currently, no blood tests are available with adequate sensitivity for early ovarian cancer detection. If successful, Pearsanta's MOT could significantly improve survival rates for women with ovarian cancer through earlier detection and more effective treatment interventions.